Kristina H Haugaa1, J Martijn Bos2, Evan J Borkenhagen3, Robert F Tarrell4, Bruce W Morlan5, Pedro J Caraballo3, Michael J Ackerman6. 1. Department of Internal Medicine, Division of Cardiovascular Diseases. 2. Department of Molecular Pharmacology and Experimental Therapeutics. 3. Department of Internal Medicine, Division of General Internal Medicine. 4. Department of Statistics. 5. Department of Health Care Policy and Research. 6. Department of Internal Medicine, Division of Cardiovascular Diseases; Department of Molecular Pharmacology and Experimental Therapeutics; Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota. Electronic address: ackerman.michael@mayo.edu.
Abstract
BACKGROUND: QT prolongation on electrocardiogram (ECG) is a risk marker of ventricular arrhythmias and all-cause mortality. Left ventricular hypertrophy (LVH) on ECG is also associated with poor outcome. Patients satisfying ECG voltage criteria for LVH frequently show concomitant QT prolongation. OBJECTIVE: This study aimed to explore the impact of marked QT prolongation on all-cause mortality in patients copresenting with LVH voltage criteria and prolonged QT on ECG. METHODS: We evaluated 3364 ECGs with corrected QT (QTc) interval ≥460 ms detected by Mayo Clinic's QT alert system from November 2010 through June 2011. Every ECG with QTc interval ≥460 ms was evaluated for the presence of LVH voltage criteria by using Sokolow-Lyon voltage, Cornell voltage, and Cornell product. RESULTS: Concomitant LVH voltage criteria were present in 181 of 3364 ECGs (5.3%) with QTc interval ≥460 ms. Mortality during a follow-up period of 217 ± 184 days was 13% (23 of 181). Independent of age and hypertension, the QTc interval predicted mortality in patients with LVH voltage criteria (hazard ratio 1.31 per 10-ms increase; 95% confidence interval 1.09-1.58; P < .01). Patients with LVH voltage criteria and QTc interval ≥500 ms had highest mortality (log rank, P < .001). CONCLUSION: The QTc interval was an independent predictor of mortality in patients with concomitant LVH voltage and prolonged QTc interval on ECG. Mortality was highest in those with QTc interval ≥500 ms. QT prolongation on ECGs with concomitant LVH voltage criteria should not be regarded as a harmless byproduct of LVH, but should be used as a significant marker of increased mortality risk similar to that in patients without LVH voltage criteria.
BACKGROUND:QT prolongation on electrocardiogram (ECG) is a risk marker of ventricular arrhythmias and all-cause mortality. Left ventricular hypertrophy (LVH) on ECG is also associated with poor outcome. Patients satisfying ECG voltage criteria for LVH frequently show concomitant QT prolongation. OBJECTIVE: This study aimed to explore the impact of marked QT prolongation on all-cause mortality in patients copresenting with LVH voltage criteria and prolonged QT on ECG. METHODS: We evaluated 3364 ECGs with corrected QT (QTc) interval ≥460 ms detected by Mayo Clinic's QT alert system from November 2010 through June 2011. Every ECG with QTc interval ≥460 ms was evaluated for the presence of LVH voltage criteria by using Sokolow-Lyon voltage, Cornell voltage, and Cornell product. RESULTS: Concomitant LVH voltage criteria were present in 181 of 3364 ECGs (5.3%) with QTc interval ≥460 ms. Mortality during a follow-up period of 217 ± 184 days was 13% (23 of 181). Independent of age and hypertension, the QTc interval predicted mortality in patients with LVH voltage criteria (hazard ratio 1.31 per 10-ms increase; 95% confidence interval 1.09-1.58; P < .01). Patients with LVH voltage criteria and QTc interval ≥500 ms had highest mortality (log rank, P < .001). CONCLUSION: The QTc interval was an independent predictor of mortality in patients with concomitant LVH voltage and prolonged QTc interval on ECG. Mortality was highest in those with QTc interval ≥500 ms. QT prolongation on ECGs with concomitant LVH voltage criteria should not be regarded as a harmless byproduct of LVH, but should be used as a significant marker of increased mortality risk similar to that in patients without LVH voltage criteria.
Authors: Christos Charalambous; James C Moon; Jeff M P Holly; Nishi Chaturvedi; Alun D Hughes; Gabriella Captur Journal: Front Cardiovasc Med Date: 2022-04-22
Authors: Markus Wallner; Deborah M Eaton; Remus M Berretta; Laura Liesinger; Matthias Schittmayer; Juergen Gindlhuber; Jichuan Wu; Mark Y Jeong; Ying H Lin; Giulia Borghetti; Sandy T Baker; Huaqing Zhao; Jessica Pfleger; Sandra Blass; Peter P Rainer; Dirk von Lewinski; Heiko Bugger; Sadia Mohsin; Wolfgang F Graier; Andreas Zirlik; Timothy A McKinsey; Ruth Birner-Gruenberger; Marla R Wolfson; Steven R Houser Journal: Sci Transl Med Date: 2020-01-08 Impact factor: 19.319
Authors: Katherine C Wu; Fiona Bhondoekhan; Sabina A Haberlen; Hiroshi Ashikaga; Todd T Brown; Matthew J Budoff; Gypsyamber D'Souza; Jared W Magnani; Lawrence A Kingsley; Frank J Palella; Joseph B Margolick; Otoniel Martínez-Maza; Sean F Altekruse; Elsayed Z Soliman; Wendy S Post Journal: Ann Noninvasive Electrocardiol Date: 2019-09-19 Impact factor: 1.468
Authors: Gabrielle Norrish; Cristian Topriceanu; Chen Qu; Ella Field; Helen Walsh; Lidia Ziółkowska; Iacopo Olivotto; Silvia Passantino; Silvia Favilli; Aris Anastasakis; Vasiliki Vlagkouli; Robert Weintraub; Ingrid King; Elena Biagini; Luca Ragni; Terrence Prendiville; Sophie Duignan; Karen McLeod; Maria Ilina; Adrian Fernández; Regina Bökenkamp; Anwar Baban; Fabrizio Drago; Peter Kubuš; Piers E F Daubeney; Sian Chivers; Georgia Sarquella-Brugada; Sergi Cesar; Chiara Marrone; Constancio Medrano; Reyes Alvarez Garcia-Roves; Orhan Uzun; Ferran Gran; Fernandez J Castro; Juan R Gimeno; Roberto Barriales-Villa; Fernando Rueda; Satish Adwani; Jonathan Searle; Tara Bharucha; Ana Siles; Ana Usano; Torsten B Rasmussen; Caroline B Jones; Toru Kubo; Jens Mogensen; Zdenka Reinhardt; Elena Cervi; Perry M Elliott; Rumana Z Omar; Juan P Kaski Journal: Eur J Prev Cardiol Date: 2022-03-30 Impact factor: 7.804